Cumberland Pharmaceuticals Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -12.2% | -90.3% | -197.9% | – | -1.8% | +77.2% | +17.1% | +33.3% | -27.9% | -110.0% | – | |
| – | +12.9% | +6.7% | +10.5% | +12.7% | +47.7% | +7.8% | -3.0% | +15.7% | +8.3% | +4.7% | -12.5% | |
| – | -18.3% | +36.9% | +74.6% | -8.3% | +8.9% | -29.6% | -29.1% | -39.7% | -18.4% | -17.3% | +35.3% | |
| – | – | +144.5% | +109.4% | -73.9% | -45.3% | +329.2% | -191.6% | – | – | – | – | |
| – | -44.7% | -269.3% | – | – | -127.9% | – | +131.5% | +34.1% | -57.8% | -72.1% | +67.3% | |
| – | -17.3% | -21.1% | -30.1% | +187.1% | -94.2% | +758.6% | -83.2% | +485.1% | -78.2% | -60.3% | -45.5% | |
| – | -61.1% | +32.8% | – | -391.5% | – | -176.5% | -71.4% | +2,624.6% | -99.2% | – | -8,236.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +23.7% | -52.8% | +47.8% | -22.7% | +21.4% | -47.0% | -25.1% | -24.1% | -29.7% | -21.8% | -54.5% | |
| – | -98.1% | +7,459.5% | +137.5% | +78.9% | -115.2% | +126.1% | – | +0.0% | -384.7% | – | -502.7% | |
| – | +212.5% | -77.9% | – | +266.5% | -171.2% | +40.1% | -50.1% | -42.0% | +260.1% | – | -3,525.8% | |
| – | – | – | – | -260.3% | – | -1,363.8% | – | -418.4% | – | – | – | |
| – | -7.3% | -149.1% | – | – | – | +17.5% | +81.4% | +6.5% | -11.6% | -114.0% | – |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.